These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 19020921

  • 1. Differences in persistence among different weekly oral bisphosphonate medications.
    Sheehy O, Kindundu CM, Barbeau M, LeLorier J.
    Osteoporos Int; 2009 Aug; 20(8):1369-76. PubMed ID: 19020921
    [Abstract] [Full Text] [Related]

  • 2. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.
    Ringe JD, Möller G.
    Rheumatol Int; 2009 Dec; 30(2):213-21. PubMed ID: 19430791
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The association between automatic generic substitution and treatment persistence with oral bisphosphonates.
    Ström O, Landfeldt E.
    Osteoporos Int; 2012 Aug; 23(8):2201-9. PubMed ID: 22120909
    [Abstract] [Full Text] [Related]

  • 5. Adherence to osteoporosis medications amongst Singaporean patients.
    Cheen MH, Kong MC, Zhang RF, Tee FM, Chandran M.
    Osteoporos Int; 2012 Mar; 23(3):1053-60. PubMed ID: 21503813
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy.
    Lindsay R, Watts NB, Lange JL, Delmas PD, Silverman SL.
    Osteoporos Int; 2013 Aug; 24(8):2345-52. PubMed ID: 23612793
    [Abstract] [Full Text] [Related]

  • 7. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
    Martin KE, Yu J, Campbell HE, Abarca J, White TJ.
    J Manag Care Pharm; 2011 Oct; 17(8):596-609. PubMed ID: 21942301
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Bisphosphonate alternative regimens for the prevention of osteoporotic fragility fractures: BLAST-OFF, a mixed-methods study.
    Sahota O, Narayanasamy M, Bastounis A, Paskins Z, Bishop S, Langley T, Gittoes N, Davis S, Baily A, Holmes M, Leonardi-Bee J.
    Health Technol Assess; 2024 Apr; 28(21):1-169. PubMed ID: 38634483
    [Abstract] [Full Text] [Related]

  • 13. [Postmenopausal osteoporosis. Bisphosphonates are not all equal].
    MMW Fortschr Med; 2009 Mar 12; 151(11):46-7. PubMed ID: 19469206
    [No Abstract] [Full Text] [Related]

  • 14. Risedronate: a new oral bisphosphonate.
    Umland EM, Boyce EG.
    Clin Ther; 2001 Sep 12; 23(9):1409-21. PubMed ID: 11589256
    [Abstract] [Full Text] [Related]

  • 15. Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations.
    Emkey R.
    MedGenMed; 2004 Jul 19; 6(3):6. PubMed ID: 15520628
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France.
    Hiligsmann M, Reginster JY.
    Osteoporos Int; 2019 Mar 19; 30(3):649-658. PubMed ID: 30701342
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis.
    Hadji P, Felsenberg D, Amling M, Hofbauer LC, Kandenwein JA, Kurth A.
    Osteoporos Int; 2014 Jan 19; 25(1):339-47. PubMed ID: 24091594
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
    Parthan A, Kruse M, Yurgin N, Huang J, Viswanathan HN, Taylor D.
    Appl Health Econ Health Policy; 2013 Oct 19; 11(5):485-97. PubMed ID: 23868102
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.